Business
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences
HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:","length":409,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","val":[{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment Conference","length":61,"tagName":"p"}]}]},{"val":[{"style":"max-width:10%;width:10%;min-width:10%;","val":[{"type":"text","content":"Date:","length":5,"tagName":"p","attribs":{}}]},{"style":"max-width:90%;width:90%;min-width:90%;","val":[{"type":"text","content":"Tuesday, September 9, 2025","length":26,"tagName":"p","attribs":{}}]}]},{"val":[{"val":[{"type":"text","content":"Format:","length":7,"tagName":"p"}]},{"val":[{"type":"text","content":"1x1 Investor Meetings Only","length":26,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]},{"val":[{"type":"text","content":" ","length":6,"tagName":"p"}]}]},{"val":[{"colspan":"2","val":[{"type":"text","content":"Morgan Stanley 23rd Annual Global Healthcare Conference ","length":55,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Date:","length":5,"tagName":"p"}]},{"val":[{"type":"text","content":"Wednesday, September 10, 2025","length":29,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":"Format:","length":7,"tagName":"p"}]},{"val":[{"type":"text","content":"Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings","length":67,"tagName":"p"}]}]},{"val":[{"val":[{"type":"text","content":" ","le...